Skip to main content

Table 1 Associations of clinicopathologic characteristics with Nav1.5 expression in 269 patients with colon cancer

From: Expression of voltage-gated sodium channel Nav1.5 in non-metastatic colon cancer and its associations with estrogen receptor (ER)-β expression and clinical outcomes

Characteristics

Total patients

Nav1.5 low expression

Nav1.5 high expression

P value

Clinical parameter

 Gender

   

0.384

  Male

145 (53.9)

18 (12.4)

127 (87.6)

 

  Female

124 (46.1)

20 (16.1)

104 (83.9)

 

 Age (years)

  ≤ 60

136 (50.6)

21 (15.4)

115 (84.6)

0.532

  > 60

133 (49.4)

17 (12.8)

116 (87.2)

 

 Tumor localization

   

0.503

  Right-sided colon

98 (36.4)

12 (12.2)

86 (87.8)

 

  Left-sided colon

171 (63.6)

26 (15.2)

145 (84.8)

 

 Preoperative serum CEA (ng/mL)a

   

0.011

  ≤ 5

154 (62.6)

29 (18.8)

125 (81.2)

 

  > 5

92 (37.4)

6 (6.5)

86 (93.5)

 

 Preoperative serum CA199 (U/mL)b

   

0.947

  ≤ 35

180 (81.1)

25 (13.9)

155 (86.1)

 

  > 35

42 (18.9)

6 (14.3)

36 (85.7)

 

 Adjuvant chemotherapy

   

0.556

  Yes

228 (84.8)

31 (81.6)

197 (85.3)

 

  No

41 (15.2)

7 (18.4)

34 (14.7)

 

Pathologic feature

 Tumor size (cm)

   

0.863

  ≤ 5

138 (51.3)

19 (13.8)

119 (86.2)

 

  > 5

131 (48.7)

19 (14.5)

112 (85.5)

 

 Tumor differentiation

   

0.983

  Well and moderate

248 (92.2)

35 (14.1)

213 (85.9)

 

  Poor

21 (7.8)

3 (14.3)

18 (85.7)

 

 T category

   

0.385

  T1

17 (6.3)

8 (47.1)

9 (52.9)

 

  T2

50 (18.6)

4 (8.0)

46 (92.0)

 

  T3

108 (40.1)

9 (8.3)

99 (91.7)

 

  T4

94 (34.9)

17 (18.1)

77 (81.9)

 

 N category

   

0.545

  N0

195 (72.5)

26 (13.3)

169 (86.7)

 

  N1-2

74 (27.5)

12 (16.2)

62 (83.8)

 

 TNM stage

   

0.836

  I

61 (22.7)

11 (18.0)

50 (82.0)

 

  II

134 (49.8)

15 (11.2)

119 (88.8)

 

  III

74 (27.5)

12 (16.2)

62 (83.8)

 

 ER-β statusc

   

0.024

  Low expression

51 (19.8)

12 (23.5)

39 (76.5)

 

  High expression

206 (80.2)

23 (11.2)

183 (88.8)

 
  1. All data are presented as number of patients followed by percentage in the parentheses
  2. ER-β estrogen receptor-β, TNM tumor-node-metastasis, CEA carcinoembryonic antigen, CA199 cancer antigen (CA) 199
  3. aThe data of preoperative CEA level were available in 246 patients
  4. bThe data of preoperative CA199 level were available in 222 patients
  5. cER-β status was evaluated in 257 patients